Nipent pentostatin: Phase II data; marketed to treat hairy cell leukemia

SUPG said that in a U.S. Phase II trial of Nipent, 6 of 10 evaluable patients with GvHD had responses, with 5 complete responses and 1 partial response. No severe infections were reported. Data were p...